vandetanib sold brand name caprelsa anticancer medication used treatment certain tumours thyroid gland acts kinase inhibitor number cell receptors mainly vascular endothelial growth factor receptor vegfr epidermal growth factor receptor egfr rettyrosine drug developed later sold rights sanofi vandetanib used treat medullary thyroid cancer adults ineligible mutation ret confers resistance vandetanib antiret people moderate severe hepatic impairment dosage vandetanib recommended safety efficacy established vandetanib contraindicated people congenital long qt common present greater people adverse effects include colds bronchitis upper respiratory tract infections urinary tract infections decreased appetite low calcium absorption insomnia depressed mood headache tingling sensations weird painful sensations dizziness blurred vision damage cornea long qt syndrome high blood pressure stomach pain diarrhea nausea vomiting indigestion sensitivity sunlight rash acne dry itchy skin nail disorders protein urine kidney stones weakness fatigue pain common present people adverse effects include pneumonia sepsis influenza cystitis sinusitis laryngitis folliculitis boils fungal infection kidney infections low thyroid hormone levels low potassium high calcium levels hyperglycemia dehydration low sodium levels anxiety tremor lethargy loss consciousness balance disorders changes sense taste visual impairment halo vision perceived light flashes glaucoma pink eye dry eye keratopathy hypertensive crisis mini strokes nose bleeds coughing blood defecating blood colitis dry mouth stomatitis constipation gastritis gallstones chemotherapyinduced acral erythema hair loss painful urination bloody urine kidney failure frequent urination urgent need urinate vandetanib reported substrate transporters interaction vandetanib may alter hepatic disposition lead transporter mediated drugdrug also vandetanib inhibitor transporter drugs prolong qt interval possibly add side effect vandetanib drug partly metabolised via liver enzyme strong inducers enzyme decrease blood plasma concentrations inhibitors significantly increase vandetanib concentrations presumably also metabolised flavin containing monooxygenase vandetanib inhibitor vascular endothelial growth factor epidermal growth factor receptor ret tyrosine kinases ret tyrosine kinases weakly inhibits vandetanib well absorbed gut reaches peak blood plasma concentrations hours application halflife days average per pharmacokinetic studies taken three months achieve steadystate concentration blood almost completely bound plasma proteins albumin metabolised ndesmethylvandetanib via vandetanibnoxide via active metabolites vandetanib excreted via faeces urine form unchanged drug vandetanib approved fda april treatment latestage thyroid vandetanib first initially marketed without trade name marketed trade name caprelsa since august genzyme acquired product astrazeneca tested vandetanib clinical trials nonsmall cell lung cancer submitted application approval ema withdrew application october trials showed benefit drug administered alongside clinical trial vandetanib plus gemcitabine versus placebo plus gemcitabine locally advanced metastatic pancreatic carcinoma negative prospective randomised doubleblind multicentre phase httpsenwikipediaorgwikivandetanib